SELLAS Life Sciences (SLS) Non-Current Deferred Tax Liability (2015 - 2021)
SELLAS Life Sciences (SLS) posted quarterly Non-Current Deferred Tax Liability of $152000.0 for Q4 2021, down 89.03% year-over-year from $1.4 million in Q4 2020, and down 36.4% quarter-over-quarter from $239000.0 in Q3 2021.
SELLAS Life Sciences (SLS) Non-Current Deferred Tax Liability (2015 - 2021) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Non-Current Deferred Tax Liability for 7 consecutive years, with $152000.0 the latest figure, recorded in Q4 2021.
- In Q4 2021, Non-Current Deferred Tax Liability fell 89.03% year-over-year to $152000.0; the TTM figure through Dec 2021 stood at $152000.0 (down 89.03% YoY), while the FY2021 annual figure was $152000.0, down 89.03% from the prior year.
- Non-Current Deferred Tax Liability eased to $152000.0 in Q4 2021 per SLS's latest filing, from $239000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $5.7 million in Q1 2017 and bottomed at $152000.0 in Q4 2021.
- Historically, Non-Current Deferred Tax Liability has averaged $1.5 million across 5 years, with a median of $357000.0 in 2018.
- Annual changes were most pronounced in 2018 — Non-Current Deferred Tax Liability slumped 89.62% — and 2020, when it surged 428.63%.
- SELLAS Life Sciences' Non-Current Deferred Tax Liability stood at $3.4 million in 2017, then plunged by 89.62% to $357000.0 in 2018, then slipped by 26.61% to $262000.0 in 2019, then soared by 428.63% to $1.4 million in 2020, then sank by 89.03% to $152000.0 in 2021.
- Business Quant data shows SLS's Non-Current Deferred Tax Liability at $152000.0 in Q4 2021, $239000.0 in Q3 2021, and $239000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 152,000.00 |
| Dec 31, 2021 | 152,000.00 |
| Sep 30, 2021 | 239,000.00 |
| Sep 30, 2021 | 239,000.00 |
| Jun 30, 2021 | 239,000.00 |
| Jun 30, 2021 | 239,000.00 |
| Mar 31, 2021 | 239,000.00 |
| Mar 31, 2021 | 239,000.00 |
| Dec 31, 2020 | 1.39 Mn |
| Dec 31, 2020 | 1.39 Mn |
| Sep 30, 2020 | 262,000.00 |
| Sep 30, 2020 | 262,000.00 |
| Jun 30, 2020 | 262,000.00 |
| Jun 30, 2020 | 262,000.00 |
| Mar 31, 2020 | 262,000.00 |
| Mar 31, 2020 | 262,000.00 |
| Dec 31, 2019 | 262,000.00 |
| Dec 31, 2019 | 262,000.00 |
| Sep 30, 2019 | 357,000.00 |
| Sep 30, 2019 | 357,000.00 |